Subcutaneous Vs Intravenous Administration Of Trastuzumab In Her2+ Breast Cancer Patients: A Macedonian Cost-Minimization Analysis.

BACKGROUND • The rising cost of cancer care has progressively become hardly sustainable for health care systems worldwide . • Trastuzumab (Herceptin®) humanized IgG1 monoclonal antibody is standard treatment for patients with early and with metastatic HER2-positive breast cancer. • SC-TRA, co-formulation of TRA with recombinant human hyaluronidase alternative to IV-TRA drug administration for shorter time period improved resource use, patient convenience and compliance available in EU since August 2013 • Recently published randomized clinical studies indicate that: SC-TRA is non-inferior compared with the intravenous administration of the drug in terms of efficacy as well as in pharmacokinetic parameters overwhelming majority of patients prefer SC-TRA over IV-TRA